Cookie policy

This site uses cookies to improve your user experience. By using this website, you agree that we can place cookies on your device. For further information, please read our Privacy And Cookies Policy

I accept the terms and conditions
Skip Ribbon Commands
Skip to main content

Occlusafe® - Occlusive micro balloon catheter

​Flow redistribution

Occlusafe allows you to redistribute the flow in such way that therapeutics agents are preferentially accumulated in the targeted lesion.

Precision

Accurate navigability allows for segmental and sub-segmental catheter positioning with Terumo hydrophilic coating.

No reflux

  • Atraumatic procedures
  • High quality occlusive balloon
  • No reflux: Complete occlusion prevents back-flow and non-target embolization3
  • Arterial flow beyond the catheter tip was maintained even after balloon inflation4
Read more Read less

​Dead volume space is 0.30 ml

​Outer diameter
dis/pro 		​ Length (cm) ​ ​Dead volume space (ml)
Main lumenInflation lumen
2.7 Fr / 2.8 Fr

(0.90 mm / 0.94 mm)

​110​0.24​0.32
​130​0.27​0.34
​150​0.30​0.36

​Including connector part

Average delivery force (N) for LifePearl microspheres through Occlusafe catheter

​​​​​All sizes of LifePearl could pass through the Occlusafe without big friction.3

Occlusafe

Item referenceOcclusafe length (cm)
OB*T41140N110
OB*T41340N130
OB*T41540N150

 

Occlusafe and Radifocus Guidewire GT with gold coil pack

​Item reference​Occlusafe length (cm)
​OB*T41140N_GTPACK​110
​OB*T41340N_GTPACK​130
​OB*T41540N_GTPACK​150

Please quote above item reference codes when placing an order.

 

 

Safety and efficacy of balloon‐occluded transcatheter arterial chemoembolization using miriplatin for hepatocellular carcinomahttps://www.terumo-europe.com/en-emea/clinical-program/Pages/Safety-and-efficacy-of-balloon‐occluded-transcatheter-arterial-chemoembolization-using-miriplatin-for-hepatocellular-carcin.aspxSafety and efficacy of balloon‐occluded transcatheter arterial chemoembolization using miriplatin for hepatocellular carcinoma<p>​Hirotaka Arai et al Gunma University Graduate School of Medicine, Maebashi, Japan</p>HayabusaArticlePage
Safety and efficacy of balloon‐occluded transcatheter arterial chemoembolization using miriplatin for hepatocellular carcinomahttps://www.terumo-europe.com/en-emea/clinicaldata/safety-and-efficacy-of-balloon‐occluded-transcatheter-arterial-chemoembolization-using-miriplatin-for-hepatocellular-carcinomaSafety and efficacy of balloon‐occluded transcatheter arterial chemoembolization using miriplatin for hepatocellular carcinoma<p>​Hirotaka Arai et al Gunma University Graduate School of Medicine, Maebashi, Japan</p>HayabusaArticlePage

 

 

 

 

 

 

​Occlusafe is not available for sale in all countries. Please contact your Terumo local sales representative for more information. Occlusafe has not been approved by the FDA and is therefore not available for sale in the U.S.A.

1 Hriotaka Arai; Hepatology Research 2015; 45, 663-666. The therapeutic effects of B-TACE were significantly higher than those of C-TACE, and improved drug uptake into cancer nodules was observed. 
2 Ishikawa T (2014):Predictive factor of local recurrence after balloon-occluded Tace with miriplatin(MPT) in hepatocellular carcinoma.PLoS ONE 9(7): e103009.doi:10.1371/journal.pone.0103009.
3 - Terumitsu Hasebe (2015): Balloon-occluded arterial stump pressure before balloon-occluded transarterial chemoembolization, Minimally Invasive Therapy & Allied Technologies, DOI: 10.3109/13645706.2015.1086381. 
- Terumitsu Hasebe; Minimally Invasive Therapy & Allied Technologies. 2015 Apr;24(2):94-100. doi: 10.3109/13645706.2014.951657. Epub 2014 Sep 29. PubMed. 
- Data on files. Reference OS-003. Terumo Europe NV 
- Hirotaka Arai; Hepatology Research 2015; 45: 6 –6 63 66 
- Hirotaka Arai; Hepatology Research 2015; 45: 6 –6 63 67 
4 Nobuyuki Takahashi: Cardiovasc Intervent Radiol (2013), 36:706-713.

Did you not find the product you were looking for?